Analysis Pharmacovigilance

Cystine/pyridoxine PSUSA ends in 'maintenance' as PRAC opens fresh safety reviews

EMA's routine periodic-safety-update outcome for cystine/pyridoxine changes nothing for licences, but it landed amid active PRAC reviews, a device recall and a reporting campaign.

VigiEye editorial · Sun 01 Nov 2026

What happened

On 30 October 2026 the European Medicines Agency posted the outcome of a periodic safety update report single assessment (PSUSA) for cystine and pyridoxine hydrochloride. The recorded regulatory outcome is 'maintenance' for the nationally authorised products concerned. In practice, the marketing authorisations stay in place.

The record is short. It does not say what the assessment found, whether any safety-related product information wording was touched, or what data the reviewers weighed. Those details sit in the full procedure documents, which the summary does not reproduce. Anything beyond the outcome label is, for now, not known from the material we have.

What 'maintenance' means, and what it doesn't

A PSUSA is the EU mechanism for assessing periodic safety update reports for the same active substance, or combination, across products and countries in a single procedure. The usual possible outcomes are maintenance, variation, suspension or revocation of the authorisations. Maintenance is the quietest of these: the benefit-risk balance remains positive and no regulatory action on the licences is needed.

It should not be read as 'nothing happened'. The assessment still took place, and the outcome page lists the nationally authorised products in scope. For marketing authorisation holders, the practical consequence of maintenance is typically that no new action is triggered. Check the published documents rather than assume that, because this record does not confirm whether any wording changes accompany the result.

One of several maintenance outcomes the same day

The cystine/pyridoxine result was not a one-off. On the same date EMA published maintenance outcomes for gliclazide, tenoxicam, and nitrofurantoin and nitrofurantoin/pyridoxine hydrochloride. The gliclazide and nitrofurantoin records also mention lists of nationally authorised products.

Taken together, these show the PSUSA system working as a steady background process. Most single assessments in this batch produced no change to the licences. That is a useful reminder for safety teams: periodic reporting is meant to confirm a stable profile as often as it is to surface new problems. Pyridoxine appears in both the cystine and nitrofurantoin combinations, but the records give no indication that the two procedures are linked.

The contrast: active signals elsewhere

The same day brought a very different kind of news from EMA's safety committee, PRAC. At its October 2026 meeting it opened a referral on flupentixol/melitracen (Deanxit) and a review of hypersensitivity clusters across all human normal immunoglobulin medicines. AIFA's summary describes the Deanxit review as concerning serious neurological and psychiatric effects, and the immunoglobulin review as concerning hypersensitivity reports linked to batches. Outcomes of both are not yet known.

Outside the EU medicines system, FDA flagged its most serious recall classification for four lots of the Werfen HemosIL AcuStar HIT-IgG(PF4-H) assay, used for heparin-induced thrombocytopenia. According to the record, the lots show a negative bias that routine calibration and quality control may miss, and a supply interruption is expected. This is a device issue rather than a drug PSUSA matter. Still, PV teams handling HIT-related case reports may want to consider whether laboratory results from affected lots could bear on case assessment. That is our reading, not an FDA statement.

Meanwhile, the Paul-Ehrlich-Institut and BfArM joined the international #MedSafetyWeek campaign, running 2–8 November, urging professionals and patients to report suspected side effects so that risks are spotted earlier. EMA also issued a dated 30 October list of centrally authorised products whose product information changed for safety reasons.

Who is affected and what to watch

Holders of nationally authorised cystine/pyridoxine products are the direct audience for the PSUSA outcome. They should confirm the published outcome against their own records and ensure their pharmacovigilance system documents it. Holders of immunoglobulin products and flupentixol/melitracen products face the more consequential near-term questions, since PRAC reviews can lead to requests for data or later regulatory action. Whether they will is not yet known.

Watch for the full PRAC documentation, any timetable for the two new reviews, and whether the MedSafetyWeek push produces a visible rise in spontaneous reporting. The pairing is instructive: periodic assessment is confirming stable profiles for older, established substances, while spontaneous reports and batch-level data are what drive the new reviews.

What to do
  • Read the full cystine/pyridoxine PSUSA documents and confirm whether any product information or MAH follow-up is attached; the summary record does not say.
  • If you hold human normal immunoglobulin or flupentixol/melitracen authorisations, prepare for possible data requests and review recent hypersensitivity (including batch-level) or neurological and psychiatric case data.
  • Review the 30 October list of centrally authorised products with safety-related product information changes against your portfolio and labelling-tracking processes.
  • Use #MedSafetyWeek (2–8 November) to remind staff and partners of internal and external adverse reaction reporting routes, and check whether any HIT cases relied on the recalled Werfen assay lots.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →